EGFR and colorectal carcinoma: In this context, it has been shown that the expression of activating k-ras mutation in CRC cells promotes the release pro-angiogenic factors, pro-inflammatory cytokines, and chemokines, that in turn, make the tumor micro-environment able to protect the tumor by multiple pro-apoptotic stimula (cytotoxic drugs, anti-EGFR mAbs, CTLs, etc.)[37–43].